Venetoclax + Fulvestrant
Phase 2TerminatedDevelopment Stage
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Sep 6, 2018 → May 6, 2021
About Venetoclax + Fulvestrant
Venetoclax + Fulvestrant is a phase 2 stage product being developed by Roche for Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03584009. Target conditions include Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03584009 | Phase 2 | Terminated |
Competing Products
20 competing products in Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer